The platform will include Lumera's NanoCapture microarrays and its ProteomicProcessor reader, which does not require molecular labels. The new system will enable researchers to perform real-time kinetic measurements of protein-protein, protein-drug, and protein-DNA interactions.
Lumera plans to bring the technology to market "as quickly as possible," according to a company statement.